SynthesisFrontiers in immunology2025
New hope for the treatment of recurrent and refractory psoriasis: NK cell immunotherapy-A scientometric analysis.
Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Trained Immunity in Autoimmunity: Friend, Foe, or Therapeutic Target?Biomedicines · 2026Article
- Rapid Resolution of Psoriasis Following Low-Dose Interleukin-2 Monotherapy: A Case Report.Biologics : targets & therapy · 2026Article
- Psoriasis as a systemic inflammatory disease: an immune set-point framework for comorbidities and relapse.Frontiers in immunology · 2026Review
- Immunosenescence in Older Patients with Psoriasis: Mechanistic Insights and Opportunities for Biologic Therapy.Psoriasis (Auckland, N.Z.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psoriasis is a chronic, relapsing, immune-mediated skin disease with a complex pathogenesis and significant individual variability in treatment response. It is characterized by a high relapse rate. In recent years, the critical role of natural killer (NK) cells in the onset and relapse of psoriasis has increasingly attracted attention, and related immune intervention strategies have become a research hotspot. Objective: This study aims to systematically review the research progress in the field of "NK cells and psoriasis" using bibliometric methods. It identifies research hotspots and key trends, constructs the knowledge structure of this field, and provides data support for related mechanistic studies and clinical translation. Methods: Based on the Web of Science Core Collection and PubMed databases, we retrieved relevant English-language literature from 2000 to 2025. Using tools such as CiteSpace and VOSviewer, we conducted keyword clustering, author and institutional collaboration analysis, journal co-citation analysis, and highly cited literature mining to create knowledge maps. Results: A total of 432 publications were included, with a sustained increase in the number of publications over time. The United States, China, and Germany were the main contributing countries, while Rockefeller University and Karolinska Institute were core institutions. The journal Frontiers in Immunology was identified as an important publication venue. Current research focuses on three hotspots: (1) the role of tissue-resident NK cells in "trained immunity" during psoriasis relapse; (2) metabolic reprogramming of NK cells in lesions, with a close correlation between their metabolic status and pro-inflammatory functions; and (3) the development of NK cell-targeted therapeutic strategies, such as dimethyl fumarate (DMF) and IL - 23 inhibitors, which show promising prospects. Conclusion: This study constructed a comprehensive knowledge map of "NK cells-psoriasis" research, clarifying the hotspots and structural characteristics. Future research will focus on two trends: (1) exploring the pivotal role of NK cells in multi-systemic immune comorbidities and (2) developing specific intervention strategies for different stages of disease progression to advance the development of precision immunotherapy for psoriasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.